MOLOGEN AG will receive patent for technological variant of MIDGE

The European Patent Office has informed MOLOGEN AG (ISIN DE 0006637200), that their patent for an important technological variant of MIDGE technology will be granted. Corresponding applications outside the European Union are pending before national patent offices.

The invention by the name of “Circle-MIDGE” relates to circular, minimalistic DNA-molecules, which, like MIDGE, only contain the medically relevant genetic information. Similar to MIDGE-TH1 such minicircles can be selectively modified at unique site to generate, for example, a TH1 type immuno-activation.

The “Circle-MIDGE” patent has great importance and impact for the protection of MOLOGEN’s MIDGE technology. “Circle-MIDGE” is likely to constitute the only producible variant of established MIDGE and MIDGE-TH1 technologies, to probably gain comparable biomedical results. Bypassing MIDGE technology patents by application of this technology variant is thereby excluded.

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview